Machine learning, predictive models, and computational biology—how AI is changing discovery workflows and probability of success.
A new McKinsey report suggests that biopharma companies must reorganize their R&D departments to fully realize AI’s potential. Without foundational structural changes, the full benefits of artificial intelligence could remain out of reach for drug developers.
A new McKinsey report suggests that biopharma companies must reorganize their R&D departments to fully realize AI’s potential. Without foundational structural changes, the full benefits of artificial intelligence could remain out of reach for drug developers.
READ MORE
Xaira Therapeutics, once a stealthy newcomer, is starting to engage external partners as it looks to validate its ambitious AI-enabled drug discovery pipeline.
The intersection of healthcare and artificial intelligence presents both opportunities and profound challenges. With AI increasingly powerful in controlled settings, questions persist about responsibility, authority, and accountability in clinical adoption.
The integration of artificial intelligence tools into mental health care is accelerating, but experts warn that clinicians are essential to ensure high-quality, ethical, and patient-centered care. This analysis explores the critical nuances that AI alone cannot address in mental health practice.
Agentic AI represents a fundamental shift from passive information providers to proactive task-doers in healthcare, potentially transforming everything from patient navigation to care coordination.
Anthropic, widely recognized as a leader in artificial intelligence, has announced its entry into drug development, raising pressing questions about AI’s potential to disrupt and redefine biopharmaceutical R&D.
Anthropic has announced the launch of Claude Science, a large language model application geared specifically for scientists and pharmaceutical researchers, signaling a significant shift in AI's role in drug development and biomedical research.
Edison Scientific joins forces with Population Health Partners to leverage advanced AI agents in the creation of cutting-edge biotech companies, signaling a new era for drug discovery and development.
As medical AI systems proliferate, the debate has shifted toward trustworthiness and transparency. Experts increasingly argue that generative AI models cannot by themselves meet the requirements of clinical rigor—fueling calls for causal, mechanism-based approaches.
Despite growing enthusiasm for AI in healthcare, many initiatives stumble after promising pilot results, failing to deliver sustained improvements at scale.
Artificial intelligence continues to revolutionize early drug discovery, enabling researchers to identify new candidate molecules quickly. However, traditional development hurdles remain critical in determining which therapies ultimately succeed.
